Competition-Based Cell Assay Employing Soluble T Cell Receptors to Assess MHC Class II Antigen Processing and Presentation.


Journal

The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209

Informations de publication

Date de publication:
18 01 2021
Historique:
received: 13 10 2020
accepted: 22 12 2020
entrez: 18 1 2021
pubmed: 19 1 2021
medline: 9 11 2021
Statut: epublish

Résumé

Accurate assessment of antigen-specific immune responses is critical in the development of safe and efficacious biotherapeutics and vaccines. Endosomal processing of a protein antigen followed by presentation on major histocompatibility complex (MHC) class II constitute necessary steps in the induction of CD4+ T cell immune responses. Current preclinical methods for assessing immunogenicity risk consist of in vitro cell-based assays and computational prediction tools. Cell-based assays are time and labor-intensive while in silico methodologies have limitations. Here, we propose a novel cell-based assay capable of investigating an antigen's endosomal processing and MHC class II presentation capabilities. This novel assay relies on competition between epitopes for MHC class II binding and employs labeled soluble T cell receptors (sTCRs) as detectors of epitope presentation.

Identifiants

pubmed: 33459871
doi: 10.1208/s12248-020-00553-x
pii: 10.1208/s12248-020-00553-x
pmc: PMC7812987
doi:

Substances chimiques

Epitopes, T-Lymphocyte 0
Histocompatibility Antigens Class II 0
Receptors, Antigen, T-Cell 0
Epoetin Alfa 64FS3BFH5W

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

26

Références

Mol Cell Proteomics. 2016 Apr;15(4):1412-23
pubmed: 26764012
Clin Immunol. 2009 May;131(2):189-201
pubmed: 19269256
Int J Cancer. 1994 Jul 1;58(1):69-79
pubmed: 7516926
J Immunol. 1982 Oct;129(4):1446-50
pubmed: 6286767
J Exp Med. 1991 Oct 1;174(4):945-8
pubmed: 1919443
PLoS One. 2011;6(11):e27930
pubmed: 22132171
J Immunol Methods. 2010 Feb 28;353(1-2):8-19
pubmed: 19925804
Nat Rev Immunol. 2015 Apr;15(4):203-16
pubmed: 25720354
Genome Med. 2018 Nov 16;10(1):84
pubmed: 30446001
J Hematol Oncol. 2019 Sep 14;12(1):99
pubmed: 31521180
Blood. 2013 Feb 28;121(9):1584-94
pubmed: 23297134
J Virol. 1998 Oct;72(10):8301-8
pubmed: 9733874
Immun Inflamm Dis. 2017 Dec;5(4):400-415
pubmed: 28560793
Nat Biotechnol. 2004 May;22(5):589-94
pubmed: 15064769
Immunology. 2010 Jul;130(3):319-28
pubmed: 20408898
MAbs. 2018 Nov-Dec;10(8):1168-1181
pubmed: 30199322
Annu Rev Immunol. 2005;23:487-513
pubmed: 15771579
Gene Ther. 2014 Jun;21(6):575-84
pubmed: 24694533
Front Immunol. 2018 Apr 11;9:674
pubmed: 29696015
BMC Bioinformatics. 2010 Nov 22;11:568
pubmed: 21092157
J Biol Chem. 2019 Apr 12;294(15):5790-5804
pubmed: 30796163
Sci Immunol. 2018 Jun 8;3(24):
pubmed: 29884618
Nat Biotechnol. 2019 Nov;37(11):1332-1343
pubmed: 31611695
Trends Immunol. 2007 Nov;28(11):482-90
pubmed: 17964218
Expert Opin Biol Ther. 2016 Aug;16(8):979-87
pubmed: 27094818
Clin Diagn Lab Immunol. 1994 Nov;1(6):696-700
pubmed: 8556523
Nat Biotechnol. 2017 Dec;35(12):1188-1195
pubmed: 29106410
Mol Immunol. 2015 Oct;67(2 Pt A):67-74
pubmed: 25708206
Nat Rev Immunol. 2003 Dec;3(12):973-83
pubmed: 14647479
J Immunol. 2003 Sep 1;171(5):2197-207
pubmed: 12928363
Clin Immunol. 2013 Dec;149(3):534-55
pubmed: 24263283
PLoS One. 2018 Nov 6;13(11):e0206654
pubmed: 30399156
Immunity. 2017 Feb 21;46(2):315-326
pubmed: 28228285
J Exp Med. 2002 Mar 4;195(5):571-81
pubmed: 11877480
Trends Biotechnol. 2006 Feb;24(2):68-75
pubmed: 16380176
Nat Rev Immunol. 2015 Mar;15(3):149-59
pubmed: 25677494
Immunology. 1993 Dec;80(4):566-73
pubmed: 7508420
PLoS One. 2015 Apr 13;10(4):e0119559
pubmed: 25875651
N Engl J Med. 2015 Sep 10;373(11):1040-7
pubmed: 26352815
Immunology. 2018 Jul;154(3):394-406
pubmed: 29315598
Oncotarget. 2018 Apr 3;9(25):17608-17619
pubmed: 29707134
J Immunol. 1994 Dec 15;153(12):5586-92
pubmed: 7527444
Immunogenetics. 2004 Mar;55(12):797-810
pubmed: 14963618
Curr Opin Pharmacol. 2005 Aug;5(4):438-43
pubmed: 15939669
Sci Transl Med. 2019 Mar 20;11(484):
pubmed: 30894502
BMC Bioinformatics. 2009 Sep 18;10:296
pubmed: 19765293
Cancer Immunol Immunother. 2004 Apr;53(4):345-57
pubmed: 14610621
Blood. 2000 Nov 15;96(10):3490-8
pubmed: 11071646

Auteurs

Carley Tasker (C)

Predictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA.

Jenny Patel (J)

Predictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA.

Vibha Jawa (V)

Predictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA.

Jad Maamary (J)

Predictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA. jad.maamary@merck.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH